Kim A Reiss (Reiss Binder), MD

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-305
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 215-360-0735
Fax: 215-662-4646
Education:
BA (Psychology)
Colby College, 2002.
Post BA (Pre-Med)
Johns Hopkins University , 2003.
MD (Medicine)
Penn State College of Medicine , 2008.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Brennan Decker, Susan M. Domchek, Kate Nathanson, Shannon Bailey, Natalie Danziger, James Thornton, Mark Hartman, Chenming Cui1, Lei Yang, Smruthy Sivakumar, Russell Madison1, Ethan Sokol, Alexa B. Schrock, Bahar Yilmazel, Douglas A Mata, Christine Vietz, Jeffrey S. Ross, Julia A. Elvin, Geoffrey R. Oxnard, Kim A. Reiss : Landscape of homologous recombination reversion mutations in pancreaticobiliary malignancies ASCO 2022, Chicago, IL June 2022.

Timothy J Brown, MD; Mark H. O’Hara, MD; Ursina Teitelbaum, MD; Thomas B. Karasic, MD; Charles Schneider, MD; Natallia Izgur, RN; Katherine Nathanson, MD; Susan M. Domchek, MD and Kim A. Reiss, MD: A Descriptive Study on the Treatment and Outcomes of Patients With Platinum-Sensitive, Advanced, BRCA or PALB2 Related Pancreatic Cancer Who Have Progressed on Rucaparib. ASCO, 2022, Chicago, IL June 2022.

Kim Anna Reiss, Yuan Yuan, Naoto T. Ueno, Melissa Lynne Johnson, Saar Gill, Elizabeth Claire Dees, Joseph Chao, Mathew Angelos, Olga Shestova, Jonathan Stuart Serody, Saul Priceman, Debora Barton, Ramona F. Swaby, Amy Ronczka, Thomas Condamine, Daniel Cushing, Rehman Qureshi, Madison Kemp, Michael Klichinsky, Yara Abdou: A phase 1, first-in-human (FIH) study of the anti-HER2 CAR macrophage CT-0508 in subjects with HER2 overexpressing solid tumors. ASCO 2022, Chicago, IL June 2022.

Kim A. Reiss, MD; Rosemarie Mick, MS; Ursina Teitelbaum, MD; Mark O’Hara, MD; Charles Schneider, MD; Ryan Massa, MD; Thomas Karasic, MD; Chioma Onyiah; Mary Kate Gosselin, RN; Alyssa Donze, RN; Susan M. Domchek, MD; Robert H. Vonderheide, MD, DPhil : A Randomized Phase Ib/II Study of Niraparib (Nira) plus Nivolumab (Nivo) or Ipilimumab (Ipi) in Patients (Pts) with Platinum-Sensitive Advanced Pancreatic Cancer (aPDAC) ASCO 2022, Chicago, IL June 2022.

Susan M. Domchek, Kim A. Reiss, Kate Nathanson, Shannon Bailey, Natalie Danziger, James Thornton, Mark Hartman, Chenming Cui, Lei Yang, Matthew Margolis, Erica Gornstein, Ethan Sokol, Douglas I. Lin, Alexa B. Schrock, Douglas A. Mata, Christine Vietz, Jeffrey S. Ross, Geoffrey R. Oxnard, Julia A. Elvin, Brennan Decker : Landscape of homologous recombination reversion mutations in gynecologic malignancies ASCO 2022, Chicago, IL June 2022.

Yara Abdou, Yuan Yuan, Naoto T Ueno, Debora Barton, Ramona F. Swaby, Amy Ronczka, Daniel . Cushing, Sascha Abramson, Thomas Condamine, Michael Klichinsky, Kim A. Reiss : A Phase 1, First in Human (FIH) Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor (CAR) in Subjects with HER2 Overexpressing Solid Tumors ASGCT, Washington, DC May 2022.

Thomas B. Karasic, Timothy J Brown, Charles J. Schneider, Ursina R. Teitelbaum, Kim A. Reiss, Tara C. Mitchell, Ryan C. Massa, Mark H. O’Hara, Lisa DiCicco, Luis Garcia-Marcano, Ravi K. Amaravadi, Peter J O’Dwyer: Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer. The Oncologist May 2022.

Kim A. Reiss et al: A phase 1, first in human (FIH) study of autologous anti-HER2 chimeric antigen receptor macrophages (CAR-M) in HER2-overexpressing solid tumors (ST). AACR, New Orleans, LA Apr 2022.

Kim A. Reiss, Yuan Yuan, Naoto T. Ueno, Yara Abdou, Debora Barton, Ramona F. Swaby, Amy Ronczka, Daniel J. Cushing, Sascha Abramso, Thomas Condamine5, Michael Klichinsky, E. Claire Dees: A Phase 1, First in Human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in participantss with HER2 overexpressing solid tumors. Annual Myeloid Network Symposium Mar 2022.

Kim A. Reiss; Yuan Yuan; Debora Barton; Amy Ronczka; Daniel Cushing; Michael Klichinsky; Elizabeth C. Dees: A phase 1, first-in-human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors. ASCO GI, San Francisco, CA Jan 2022.

back to top
Last updated: 06/22/2022
The Trustees of the University of Pennsylvania